Bile salt-induced calcium fluxes in artificial phospholipid vesicles.
The ionic permeability of selected biological membranes is increased by bile salts. To examine changes in calcium permeability during the exposure of artificial membranes to bile salts, we investigated calcium uptake by unilamellar and multilamellar phospholipid vesicles. In the presence of 750 microM taurodeoxycholate, uptake of radiolabelled calcium by unilamellar vesicles increased 2.5-fold over control values. Calcium uptake by multilamellar vesicles as measured with a free calcium indicator, arsenazo III, increased 2.2- or 21-fold in the presence of 60 microM lithocholate or 3 beta-hydroxy-5-cholenoate, respectively. Results were directly influenced by experimental variables such as bile salt hydrophobicity, external calcium concentration, and the bile salt/lipid molar ratio. Observed membrane solubilization was minimal despite increased calcium permeability. Comparison of radiolabelled calcium uptake with radiolabelled sodium or radiolabelled rubidium uptake indicated that bile salt-dependent calcium uptake was 60-140-times greater than bile salt-dependent uptake of either monovalent cation. In an effort to delineate forces affecting calcium translocation, vesicles were exposed either to valinomycin, which induced an electrochemical gradient across the membrane, or to nigericin, which induced a proton gradient. Exposure to valinomycin minimally influenced bile salt-induced calcium uptake while exposure to nigericin significantly promoted uptake by 40-70%. The results suggest that bile salts promote calcium uptake by a mechanism which may be similar to those of other carboxylic ionophores.
Oelberg
D G
DG
University of Texas Medical School, Department of Pediatrics, Houston 77225.
Wang
L B
LB
Sackman
J W
JW
Adcock
E W
EW
Lester
R
R
Dubinsky
W P
WP
D001150:Arsenazo III; D001647:Bile Acids and Salts / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002414:Cations, Monovalent; D002463:Cell Membrane Permeability; D002793:Cholic Acids / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004563:Electrochemistry; D008081:Liposomes / Q000378:metabolism*; D008095:Lithocholic Acid / Q000494:pharmacology; D009550:Nigericin / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism*; D011522:Protons; D012413:Rubidium / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013657:Taurodeoxycholic Acid / Q000494:pharmacology; D014634:Valinomycin / Q000494:pharmacology
D001647:Bile Acids and Salts; D002414:Cations, Monovalent; D002793:Cholic Acids; D008081:Liposomes; D010743:Phospholipids; D011522:Protons; D001150:Arsenazo III; D014634:Valinomycin; D013657:Taurodeoxycholic Acid; D008095:Lithocholic Acid; C026883:3 beta-hydroxychol-3-en-24-oic acid; D012964:Sodium; D012413:Rubidium; D009550:Nigericin; D002118:Calcium